{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:12:08Z","timestamp":1772273528282,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV-1 protease inhibitors (PIs), such as darunavir (DRV), are the key component of antiretroviral therapy. However, HIV-1 often acquires resistance to PIs. Here, seven novel PIs were synthesized, by introducing single atom changes such as an exchange of a sulfur to an oxygen, scission of a single bond in P2\u2032-cyclopropylaminobenzothiazole (or -oxazole), and\/or P1-benzene ring with fluorine scan of mono- or bis-fluorine atoms around DRV\u2019s scaffold. X-ray structural analyses of the PIs complexed with wild-type Protease (PR<jats:sub>WT<\/jats:sub>) and highly-multi-PI-resistance-associated PR<jats:sub>DRV<\/jats:sub><jats:sup>R<\/jats:sup><jats:sub>P51<\/jats:sub> revealed that the PIs better adapt to structural plasticity in PR with resistance-associated amino acid substitutions by formation of optimal sulfur bond and adaptation of cyclopropyl ring in the S2\u2032-subsite. Furthermore, these PIs displayed increased cell permeability and extreme anti-HIV-1 potency compared to DRV. Our work provides the basis for developing novel PIs with high potency against PI-resistant HIV-1 variants with a high genetic barrier.<\/jats:p>","DOI":"10.1038\/s41598-020-65993-z","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T10:04:05Z","timestamp":1593511445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity"],"prefix":"10.1038","volume":"10","author":[{"given":"Haydar","family":"Bulut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Aoki-Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debananda","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalapala Venkateswara","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanth R.","family":"Nyalapatla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"65993_CR1","doi-asserted-by":"publisher","first-page":"e28020","DOI":"10.7554\/eLife.28020","volume":"6","author":"M Aoki","year":"2017","unstructured":"Aoki, M. et al. A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. Elife. 6, e28020 (2017).","journal-title":"Elife."},{"issue":"12","key":"65993_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2424","volume":"6","author":"E De Clercq","year":"2007","unstructured":"De Clercq, E. The design of drugs for HIV and HCV. Nature reviews. Drug discovery. 6(12), 1001\u201318 (2007).","journal-title":"Nature reviews. Drug discovery."},{"issue":"6","key":"65993_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/aid.1989.5.577","volume":"5","author":"S Erickson-Viitanen","year":"1989","unstructured":"Erickson-Viitanen, S. et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses. 5(6), 577\u201391 (1989).","journal-title":"AIDS Res Hum Retroviruses."},{"key":"65993_CR4","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"AK Ghosh","year":"2016","unstructured":"Ghosh, A. K., Osswald, H. L. & Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS. J Med Chem. 59, 5172\u20135208 (2016).","journal-title":"J Med Chem."},{"issue":"30","key":"65993_CR5","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.2174\/09298673113209990135","volume":"20","author":"C Calugi","year":"2013","unstructured":"Calugi, C., Guarna, A. & Trabocchi, A. Heterocyclic HIV-protease inhibitors. Current medicinal chemistry. 20(30), 3693\u20133710 (2013).","journal-title":"Current medicinal chemistry."},{"key":"65993_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2147\/TCRM.S1709","volume":"4","author":"CL Tremblay","year":"2008","unstructured":"Tremblay, C. L. Combating HIV resistance \u2013 focus on darunavir. Ther Clin Risk Manag. 4, 759\u2013766 (2008).","journal-title":"Ther Clin Risk Manag."},{"issue":"12","key":"65993_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/aid.2018.0100","volume":"34","author":"K Brown","year":"2018","unstructured":"Brown, K. et al. Prevalence of Darunavir Resistance in the United States from 2010 to 2017. AIDS research and human retroviruses 34(12), 1036\u20131043 (2018).","journal-title":"AIDS research and human retroviruses"},{"key":"65993_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.2460925","volume":"242","author":"JD Roberts","year":"1988","unstructured":"Roberts, J. D., Bebenek, K. & Kunkel, T. A. The accuracy of reverse transcriptase from HIV-1. Science. 242, 1171\u20131173 (1988).","journal-title":"Science."},{"key":"65993_CR9","doi-asserted-by":"publisher","first-page":"28709","DOI":"10.1074\/jbc.M703938200","volume":"282","author":"Y Koh","year":"2007","unstructured":"Koh, Y. et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 282, 28709\u201328720 (2007).","journal-title":"J Biol Chem."},{"issue":"10","key":"65993_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/14656566.2018.1484901","volume":"19","author":"V Spagnuolo","year":"2018","unstructured":"Spagnuolo, V., Castagna, A. & Lazzarin, A. Darunavir for the treatment of HIV infection. Expert Opin Pharmacother. 19(10), 1149\u20131163 (2018).","journal-title":"Expert Opin Pharmacother."},{"key":"65993_CR11","doi-asserted-by":"publisher","first-page":"11961","DOI":"10.1128\/JVI.00967-10","volume":"84","author":"Y Koh","year":"2010","unstructured":"Koh, Y. et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variant by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol. 84, 11961\u201311969 (2010).","journal-title":"J Virol."},{"key":"65993_CR12","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/anie.201102762","volume":"51","author":"AK Ghosh","year":"2012","unstructured":"Ghosh, A. K., Anderson, D. D., Weber, I. T. & Mitsuya, H. Enhancing protein backbone binding\u2013a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl. 51, 1778\u20131802 (2012).","journal-title":"Angew Chem Int Ed Engl."},{"issue":"43","key":"65993_CR13","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1021\/jacs.8b07366","volume":"140","author":"IW Windsor","year":"2018","unstructured":"Windsor, I. W. et al. Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid. J Am Chem Soc. 140(43), 14015\u201314018 (2018).","journal-title":"J Am Chem Soc."},{"issue":"6","key":"65993_CR14","first-page":"63","volume":"24","author":"SI Hattori","year":"2019","unstructured":"Hattori, S. I. et al. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. Antimicrob Agents Chemother. 24(6), 63 (2019).","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"65993_CR15","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1021\/acs.jctc.8b00097","volume":"14","author":"F Leidner","year":"2018","unstructured":"Leidner, F., Kurt Yilmaz, N., Paulsen, J., Muller, Y. A. & Schiffer, C. A. Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease. J Chem Theory Comput. May 8 14(5), 2784\u20132796 (2018).","journal-title":"J Chem Theory Comput. May 8"},{"issue":"4","key":"65993_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.bbrc.2011.08.045","volume":"412","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease. Biochem Biophys Res Commun. 9 412(4), 737\u201342 (2011).","journal-title":"Biochem Biophys Res Commun. 9"},{"key":"65993_CR17","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1021\/acs.jmedchem.7b00172","volume":"60","author":"AK Ghosh","year":"2017","unstructured":"Ghosh, A. K. et al. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. J Med Chem. 60, 4267\u20134278 (2017).","journal-title":"J Med Chem."},{"key":"65993_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1021\/jm00054a015","volume":"36","author":"AK Ghosh","year":"1993","unstructured":"Ghosh, A. K. et al. 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. Med. Chem. 36, 292\u2013294 (1993).","journal-title":"Med. Chem."},{"key":"65993_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1021\/jm00004a001","volume":"38","author":"ML Vazquez","year":"1995","unstructured":"Vazquez, M. L. et al. Inhibitors of HIV-1 Protease Containing the Novel and Potent (R)-(Hydroxyethyl)sulfonamide Isostere. J. Med. Chem. 38, 581\u2013584 (1995).","journal-title":"J. Med. Chem."},{"issue":"52","key":"65993_CR20","doi-asserted-by":"publisher","first-page":"20982","DOI":"10.1073\/pnas.1111202108","volume":"108","author":"VY Torbeev","year":"2011","unstructured":"Torbeev, V. Y. et al. Protein conformational dynamics in the mechanism of HIV-1 protease catalysis. Proc Natl Acad Sci USA Dec 27 108(52), 20982\u20137 (2011).","journal-title":"Proc Natl Acad Sci USA Dec 27"},{"issue":"1","key":"65993_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbrc.2019.08.126","volume":"519","author":"DW Kneller","year":"2019","unstructured":"Kneller, D. W., Agniswamy, J., Ghosh, A. K. & Weber, I. T. Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20. Biochem Biophys Res Commun. 29; 519(1), 61\u201366 (2019).","journal-title":"Biochem Biophys Res Commun. 29;"},{"issue":"5","key":"65993_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1021\/ar950207a","volume":"29","author":"KB Wiberg","year":"1996","unstructured":"Wiberg, K. B. Bent Bonds in Organic CompoundsAcc. Chem. Res. 29(5), 229\u2013234 (1996).","journal-title":"Chem. Res."},{"key":"65993_CR23","doi-asserted-by":"crossref","unstructured":"Kuiper, B. D. et al. The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops. Biochemistry and biophysics reports vol. 2 160-165. 12 Jun. (2015).","DOI":"10.1016\/j.bbrep.2015.06.003"},{"issue":"22","key":"65993_CR24","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1111\/j.1432-1033.2004.04431.x","volume":"271","author":"J Lindberg","year":"2004","unstructured":"Lindberg, J. et al. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1\/P1\u2032-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy. Eur J Biochem. 271(22), 4594\u20134602 (2004).","journal-title":"Eur J Biochem."},{"key":"65993_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","volume":"41","author":"BK Park","year":"2001","unstructured":"Park, B. K., Kitteringham, N. R. & O\u2019Neill, P. M. Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol. 41, 443\u2013470 (2001).","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"65993_CR26","doi-asserted-by":"crossref","unstructured":"Wang, J. et al. Chem Rev. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001\u20132011). 114, 2432-506 (2014).","DOI":"10.1021\/cr4002879"},{"issue":"3","key":"65993_CR27","doi-asserted-by":"publisher","first-page":"E745","DOI":"10.3390\/molecules25030745","volume":"25","author":"BG de la Torre","year":"2020","unstructured":"de la Torre, B. G. & Albericio, F. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 9 25(3), E745 (2020).","journal-title":"Molecules. 9"},{"issue":"5","key":"65993_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/cbic.200300907","volume":"5","author":"JA Olsen","year":"2004","unstructured":"Olsen, J. A. et al. Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles. Chembiochem. 5(5), 666\u201375 (2004).","journal-title":"Chembiochem."},{"key":"65993_CR29","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1021\/acs.jcim.6b00236","volume":"56","author":"MR Koebel","year":"2016","unstructured":"Koebel, M. R. et al. S\u00b7\u00b7\u00b7O and S\u00b7\u00b7\u00b7N Sulfur Bonding Interactions in Protein\u2013Ligand Complexes: Empirical Considerations and Scoring Function. J Chem Inf Model 56, 2298\u20132309 (2016).","journal-title":"J Chem Inf Model"},{"key":"65993_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2174\/1568026615666150915111741","volume":"16","author":"M Feng","year":"2016","unstructured":"Feng, M., Tang, B., Liang, S. H. & Jiang, X. Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry. Curr. Top. Med. Chem. 16, 1200\u20131216 (2016).","journal-title":"Curr. Top. Med. Chem."},{"key":"65993_CR31","doi-asserted-by":"publisher","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","volume":"59","author":"TT Talele","year":"2016","unstructured":"Talele, T. T. The \u201cCyclopropyl Fragment\u201d is a Versatile Player that Frequently Appears in Preclinical\/Clinical Drug Molecules. J Med Chem 59, 8712\u20138756 (2016).","journal-title":"J Med Chem"},{"issue":"7","key":"65993_CR32","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1128\/AAC.00107-14","volume":"58","author":"RS Yedidi","year":"2014","unstructured":"Yedidi, R. S. et al. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Antimicrobial agents and chemotherapy. 58(7), 3679\u201388 (2014).","journal-title":"Antimicrobial agents and chemotherapy."},{"issue":"33","key":"65993_CR33","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1073\/pnas.1400027111","volume":"111","author":"H Hayashi","year":"2014","unstructured":"Hayashi, H. et al. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc Natl Acad Sci USA 111(33), 12234\u20139 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"65993_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307\u201326 (1997).","journal-title":"Methods Enzymol"},{"issue":"Pt 2","key":"65993_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1107\/S2059798317017235","volume":"74","author":"G Winter","year":"2018","unstructured":"Winter, G. et al. DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol. 74(Pt 2), 85\u201397 (2018).","journal-title":"Acta Crystallogr D Struct Biol."},{"issue":"Pt 4","key":"65993_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. Journal of applied crystallography. 40(Pt 4), 658\u2013674 (2007).","journal-title":"Journal of applied crystallography."},{"issue":"Pt 4","key":"65993_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta crystallographica. Section D, Biological crystallography. 67(Pt 4), 355\u201367 (2011).","journal-title":"Acta crystallographica. Section D, Biological crystallography."},{"issue":"Pt 2","key":"65993_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography. 66(Pt 2), 213\u201321 (2010).","journal-title":"Section D, Biological crystallography."},{"key":"65993_CR39","doi-asserted-by":"crossref","unstructured":"Schuttelkopf, A. W., van Aalten, D. M. PRODRG: a tool for high-throughput crystallog-raphy of protein-ligand complexes. Acta crystallo-graphica. Section D, Biological crystallography 60 (Pt 8), 1355-63. 30 (2004).","DOI":"10.1107\/S0907444904011679"},{"key":"65993_CR40","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"65993_CR41","unstructured":"DeLano, W. L. The PyMOL Molecular Graphics System. (2002)."},{"key":"65993_CR42","doi-asserted-by":"crossref","unstructured":"C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera\u2013a visualization system for exploratory research and analysis. Journal of computational chemistry, 25(13), 1605\u20131612.","DOI":"10.1002\/jcc.20084"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65993-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65993-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65993-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:16:24Z","timestamp":1670332584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65993-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65993-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10664"}}